Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

January 30, 2027

Conditions
Mild to Severe Crohns Disease
Interventions
DIETARY_SUPPLEMENT

Bacillus subtilis Capsules

"Bacillus subtilis is a type of probiotic. Studies have found that supplementation with Bacillus subtilis can effectively maintain the remission of inflammatory bowel disease by protecting intestinal integrity, regulating epithelial proliferation, and reshaping the structure and function of the microbiota.~Bacillus subtilis capsules are a Bacillus supplement containing 3×10⁹ CFU of Bacillus subtilis per capsule. Patients in the Bacillus subtilis supplementation group take Bacillus subtilis capsules orally once a day, one capsule each time, for 12 weeks."

Trial Locations (1)

410013

RECRUITING

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
collaborator

RenJi Hospital

OTHER

lead

The Third Xiangya Hospital of Central South University

OTHER

NCT07123207 - Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease | Biotech Hunter | Biotech Hunter